Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services

Contract Services

Gilead expands hepatitis C generic licensing agreements to include investigational NS5A inhibitor GS-5816 Gilead Sciences has expanded its hepatitis C generic licensing agreements to include the investigational NS5A inhibitor GS-5816, which is being evaluated in Phase 3 clinical studies as part of a single tablet regimen that combines the compound and sofosbuvir for the treatment of all six genotypes of hepatitis C.
Contract Research & Services > Contract Services > News
DynPort Vaccine lands $90m follow-on clinical trials contract with NIAID By PBR Staff Writer
Computer Sciences Corporation's (CSC) unit DynPort Vaccine Company (DVC) has secured a $90m follow-on contract to continue supporting the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Contract Research & Services > Contract Services > News Solasia, Meiji Seika Pharma enter into license agreement for darinaparsin Solasia Pharma announced that Solasia and Meiji Seika Pharma have entered into a license agreement for the development and commercialization of darinaparsin (intravenous formulation) in Japan.
Contract Research & Services > Contract Services > News
See more Contract Services news

Latest Contract Services News and Insight

View all Contract Services news or find news targeted to your interests
Solasia, Meiji Seika Pharma enter into license agreement for darinaparsin
Solasia Pharma announced that Solasia and Meiji Seika Pharma have entered into a license agreement for the development and commercialization of darinaparsin (intravenous formulation) in Japan.
Contract Research & Services > Contract Services > News
Neuropore, UCB partner to develop new treatment for Parkinson’s disease
By PBR Staff Writer
US-based Neuropore Therapies has entered into a nagreement with Belgian biopharmaceutical firm UCB to develop and commercialize therapeutic products to slow the progression of Parkinson’s disease (PD) and related disorders.
Contract Research & Services > Contract Services > News
Depomed agrees to buy Janssen's Nucynta US license for $1.05bn
By PBR Staff Writer
US-based pharmaceutical firm Depomed has entered into a definitive agreement to acquire the US rights to the Nucynta franchise from Janssen Pharmaceuticals for $1.05bn.
Contract Research & Services > Contract Services > News
3SBio inks patent license deal with PharmAbcine for DIG-KT
3SBio, a China-based biotechnology firm, has entered into an exclusive licensing deal with PharmAbcine for the development, manufacturing and marketing of DIG-KT, a bi-specific monoclonal antibody (mAb) targeting both VEGFR2/KDR and Tie-2 pathways for cancer in the territory of Greater China (including mainland China, Taiwan, Hong Kong and Macau) and Korea. The deal included undisclosed upfront, milestone and royalty payments.
Contract Research & Services > Contract Services > News
KalGene signs license deal with NRC to develop new Alzheimer's therapeutics
National Research Council of Canada (NRC) has granted KalGene Pharmaceuticals an exclusive worldwide license for a therapeutic molecule against Alzheimer's disease.
Contract Research & Services > Contract Services > News
Roche enters into antibiotic license deal with Meiji and Fedora
By PBR Staff Writer
Roche has entered into a license agreement with Meiji Seika Pharma (Meiji) and Fedora to develop and commercialize OP0595, a beta-lactamase inhibitor currently in Phase I clinical development.
Contract Research & Services > Contract Services > News
Prasco, Takeda partner to market authorized generic of Colcrys tablets in US
By PBR Staff Writer
Prasco Laboratories has entered into a distribution and supply agreement with Takeda Pharmaceuticals USA (TPUSA) for the distribution rights of Colchicine Tablets, USP, the Authorized Generic (AG) version of Colcrys (colchicine, USP) Tablets in the US.
Contract Research & Services > Contract Services > News
MedImmune, Omnis Pharmaceuticals enter cancer immunotherapy deal
By PBR Staff Writer
MedImmune, AstraZeneca's global biologics research and development arm, has entered into a licensing agreement with Omnis Pharmaceuticals (Omnis), a US-based biotechnology firm focused on the development of oncolytic viruses, which are designed to target tumor cells with the killing potency of viruses.
Contract Research & Services > Contract Services > News
Kyowa Hakko to develop and commercialize Syndax's entinostat in Japan and Korea
By PBR Staff Writer
Kyowa Hakko Kirin (KHK) has entered into a license agreement for the exclusive rights to develop and commercialize Syndax Pharmaceuticals' entinostat in Japan and Korea.
Contract Research & Services > Contract Services > News
Nuo Therapeutics inks licensing deal with Rohto for Aurix in Japan
By PBR Staff Writer
Nuo Therapeutics has signed an exclusive licensing and distribution agreement with Japan-based Rohto Pharmaceutical for the first platelet and plasma therapy system, Aurix.
Contract Research & Services > Contract Services > News
View all Contract Services news or find news targeted to your interests

Buy the latest industry research online today!
Shire Plc : Pharmaceuticals & Healthcare - Company Profile, SWOT & Financial Report 03 October 2013 This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250